INCYTE CORP (INCY)
A+
Pipeline Grade
Financial Position (from SEC Filings)
$3,463.0M
Cash & Equivalents
$369.4M
Quarterly Burn Rate
$23,317M
Market Cap
Estimated from most recent SEC quarterly filing. View SEC filings
Drug Pipeline (4 Assets)
| Drug | Phase | Indications |
|---|---|---|
|
RUXOLITINIB PHOSPHATE
OPZELURA |
APPROVED | Accelerated Phase Chronic Myelogenous Leukemia, Accelerated Phase Chronic Myeloid Leukemia, Accelerated/Blast-phase Myeloproliferative Neoplasm, Acne Inversa, Acute Leukemia (Category), Acute Lymphoblastic Leukemia, Acute Lymphoblastic Lymphoma, Acute Lymphocytic Leukemia, Acute Lymphoid Leukemia, Acute Lymphoid Leukemia (ALL), Acute Myelogenous Leukemia, Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Acute-graft-versus-host Disease, Adult T-cell Leukemia/Lymphoma, Adult-type Diffuse Gliomas, Adults Patients Having Non Severe HLH, Advanced and/or Metastatic Solid Tumors, Advanced Cancer, Advanced Cholangiocarcinoma, Advanced Cutaneous Squamous Cell Carcinoma, Advanced Hepatocellular Carcinoma, Advanced Leiomyosarcoma, Advanced Malignancies, Advanced Malignant Solid Neoplasm, Advanced Myxoid Liposarcoma, Advanced or Metastatic Solid Tumors, Advanced Pancreatic Carcinoma, Advanced Soft Tissue Sarcoma, Advanced Solid Tumor, Advanced Solid Tumors, Advanced Synovial |
|
RETIFANLIMAB-DLWR
ZYNYZ |
APPROVED | — |
|
PEMIGATINIB
PEMAZYRE |
APPROVED | — |
|
axatilimab-csfr
NIKTIMVO |
APPROVED | — |
Upcoming Catalysts
| Date | Event | Drug |
|---|---|---|
| 2026-07-13 | Phase3 Readout | — |
| 2026-07-22 | Phase2 Readout | — |
| 2026-08-10 | Phase3 Readout | — |
| 2026-09-01 | Phase3 Readout | — |
| 2026-09-03 | Phase1 Readout | — |
| 2026-09-28 | Phase2 Readout | — |
| 2026-10-09 | Phase3 Readout | — |
| 2026-10-09 | Phase3 Readout | — |
| 2026-10-19 | Phase1 Readout | — |
| 2026-10-19 | Phase3 Readout | — |
| 2026-10-19 | Phase3 Readout | — |
| 2026-11-20 | Phase2 Readout | — |
| 2026-12-09 | Phase1 Readout | — |
| 2026-12-26 | Phase3 Readout | — |
| 2027-01-01 | Phase1 Readout | — |
| 2027-01-04 | Phase1 Readout | — |
| 2027-01-13 | Phase1 Readout | — |
| 2027-03-27 | Phase1 Readout | — |
| 2027-04-13 | Phase1 Readout | — |
| 2027-04-27 | Phase2 Readout | — |
Active Clinical Trials (50)
| NCT # | Title | Phase | Status | Enrollment |
|---|---|---|---|---|
| NCT06627335 | An Observational Retrospective Cohort Study Being Conducted in Women With Atopic Dermatitis Exposed to Ruxolitinib Cream... | OTHER | Recruiting | 5,621 |
| NCT05919511 | Observational Study for Patients at Risk for Chronic Graft-Versus-Host Disease | OTHER | Recruiting | 1,500 |
| NCT06259669 | Study to Compare Maternal, Fetal, and Infant Outcomes of Women With Mild to Moderate Atopic Dermatitis Exposed to Ruxoli... | OTHER | Recruiting | 958 |
| NCT06958211 | Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Hidradenitis Suppurativa (TRuE-HS2) | PHASE3 | Recruiting | 550 |
| NCT07284849 | A Study to Evaluate the Efficacy and Safety of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 i... | PHASE3 | Recruiting | 700 |
| NCT06832618 | A Study to Assess the Efficacy and Safety of Ruxolitinib Cream in Children and Adolescents (6 to <18 Years Old) With Mod... | PHASE3 | Active Not Recruiting | 159 |
| NCT06212999 | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenit... | PHASE3 | Active Not Recruiting | 617 |
| NCT06113471 | A Study to Evaluate Efficacy and Safety of Povorcitinib in Participants With Nonsegmental Vitiligo (STOP-V2) | PHASE3 | Active Not Recruiting | 450 |
| NCT06959225 | Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Hidradenitis Suppurativa (TRuE-HS1) | PHASE3 | Recruiting | 550 |
| NCT06516965 | A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN2) | PHASE3 | Active Not Recruiting | 346 |
| NCT06804811 | A Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Children (6 to < 12 Years Old) With Nonsegmental Vit... | PHASE3 | Recruiting | 250 |
| NCT06821542 | A Study to Evaluate Axatilimab Versus Best Available Therapy in Participants With Chronic Graft Versus Host Disease Afte... | PHASE3 | Active Not Recruiting | 9 |
| NCT06585774 | A Study to Evaluate Axatilimab and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease | PHASE3 | Recruiting | 240 |
| NCT06113445 | A Study to Evaluate Efficacy and Safety of Povorcitinib in Participants With Nonsegmental Vitiligo (STOP-V1) | PHASE3 | Active Not Recruiting | 467 |
| NCT06855498 | Rollover Study for Participants Previously Enrolled in Clinical Trials of Povorcitinib | PHASE3 | Recruiting | 600 |
| NCT06516952 | A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1) | PHASE3 | Active Not Recruiting | 349 |
| NCT07522073 | A Study to Evaluate Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D-Mutated Metastatic Pancre... | PHASE3 | Recruiting | 588 |
| NCT04824092 | Tafasitamab + Lenalidomide + R-CHOP Versus R-CHOP in Newly Diagnosed High-intermediate and High Risk DLBCL Patients | PHASE3 | Active Not Recruiting | 899 |
| NCT06615050 | A Study of Tacrolimus/Methotrexate/Ruxolitinib Versus Post-Transplant Cyclophosphamide/Tacrolimus/Mycophenolate Mofetil ... | PHASE3 | Recruiting | 572 |
| NCT06548360 | A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Pediatric Participants With Nonsegmental Vitiligo | PHASE3 | Recruiting | 180 |
| NCT05429268 | Study to Evaluate the Safety and Efficacy of Tafasitamab Plus Lenalidomide in Participants With Relapsed or Refractory D... | PHASE3 | Active Not Recruiting | 82 |
| NCT06873789 | A Study to Evaluate INCB177054 in Participants With Select Advanced or Metastatic Solid Tumors | PHASE2 | Active Not Recruiting | 9 |
| NCT05888844 | A Study to Evaluate INCB099280 in Participants With Advanced Cutaneous Squamous Cell Carcinoma | PHASE2 | Active Not Recruiting | 63 |
| NCT05090891 | To Assess the Efficacy, Safety, and Tolerability of INCB000928 in Participants With Fibrodysplasia Ossificans Progressiv... | PHASE2 | Recruiting | 98 |
| NCT07213973 | Pharmacokinetics, Safety, and Efficacy of Povorcitinib in Adolescent Participants With Moderate to Severe Hidradenitis S... | PHASE2 | Recruiting | 40 |
| NCT06843408 | A Ph1b/2 Study of Axatilimab Monotherapy in Chinese Participants With Recurrent or Refractory cGVHD | PHASE2 | Recruiting | 30 |
| NCT07023627 | A Study of INCB123667 in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression | PHASE2 | Recruiting | 160 |
| NCT05851443 | A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Inadequately Controlled Moderate ... | PHASE2 | Active Not Recruiting | 247 |
| NCT05879822 | A Study to Evaluate INCB099280 in Participants With Select Solid Tumors Who Are Immune Checkpoint Inhibitor Naive | PHASE2 | Active Not Recruiting | 73 |
| NCT07104565 | Study to Assess the Safety and Tolerability of Tafasitamab in Adult Participants With Primary Autoimmune Blood Cell Diso... | PHASE2 | Recruiting | 56 |
| NCT06388564 | A Study to Evaluate the Safety and Efficacy of Axatilimab in Combination With Ruxolitinib in Participants With Newly Dia... | PHASE2 | Active Not Recruiting | 130 |
| NCT07124078 | A Study to Evaluate Axatilimab Versus Best Available Therapy in Pediatric Participants With Chronic Graft-Versus-Host Di... | PHASE2 | Recruiting | 60 |
| NCT04455841 | INCB000928 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Anemia Due to Myeloprol... | PHASE2 | Active Not Recruiting | 84 |
| NCT03934372 | Safety and Efficacy of Ponatinib for Treatment of Pediatric Recurrent or Refractory Leukemias, Lymphomas or Solid Tumors | PHASE2 | Recruiting | 70 |
| NCT06465433 | Extension Study to Provide Continued Treatment for Patients With Hematologic Malignancies Previously Enrolled in Studies... | PHASE2 | Recruiting | 25 |
| NCT02955940 | An Open-Label Study to Enable Continued Treatment Access for Subjects Previously Enrolled in Studies of Ruxolitinib | PHASE2 | Active Not Recruiting | 10 |
| NCT07448155 | A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of INCA033989 Following Subcutaneous or Intravenous A... | PHASE1 | Active Not Recruiting | 72 |
| NCT06008808 | Ruxolitinib With and Without CTLA-4 Ig Abatacept for the Prophylaxis of Graft-Versus-Host Disease and Cytokine Release S... | PHASE1 | Recruiting | 41 |
| NCT07588139 | A Study to Evaluate Dermal Open-Flow Microperfusion and Plasma Pharmacokinetic Study of Multiple Doses of Oral Povorciti... | PHASE1 | Recruiting | 24 |
| NCT07049575 | Study to Evaluate the Maximal Use of Ruxolitinib Cream in Adult and Adolescent Participants With Hidradenitis Suppurativ... | PHASE1 | Recruiting | 24 |
| NCT05836324 | A Study to Evaluate the Safety of INCA33890 in Participants With Advanced or Metastatic Solid Tumors | PHASE1 | Recruiting | 408 |
| NCT06179160 | A Study to Evaluate INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation | PHASE1 | Recruiting | 710 |
| NCT07559474 | A Study to Assess the Safety and Pharmacokinetics of INCB123667 When Administered Orally to Adult Participants With Mode... | PHASE1 | Recruiting | 16 |
| NCT06034002 | A Study to Evaluate INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Mye... | PHASE1 | Recruiting | 290 |
| NCT05238922 | Study of INCB123667 in Subjects With Advanced Solid Tumors | PHASE1 | Recruiting | 604 |
| NCT07008118 | A Study to Evaluate INCA035784 in Participants With Myeloproliferative Neoplasms | PHASE1 | Recruiting | 120 |
| NCT07441694 | Study of INCA036978 in Participants With Myeloproliferative Neoplasms | PHASE1 | Recruiting | 218 |
| NCT07559396 | A Study to Assess the Safety and Pharmacokinetics of INCB123667 When Administered Orally to Adult Participants With Seve... | PHASE1 | Recruiting | 16 |
| NCT06818812 | A Study to Evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation | PHASE1 | Active Not Recruiting | 30 |
| NCT06313593 | A Study to Evaluate the Safety, Tolerability of INCB160058 in Participants With Myeloproliferative Neoplasms | PHASE1 | Recruiting | 186 |
Source: ClinicalTrials.gov. Trial status last updated by sponsor — may not reflect current state.